ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual Meeting
5/16/2013 9:40:47 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON, May 16, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced promising results from nonclinical and Phase 1 studies in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Findings were presented in an oral session at the 16th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 15-18 in Salt Lake City, Utah. A presentation of the study, titled "Nonclinical and Phase I Clinical Studies with a Regulated Adenoviral Gene Delivery of IL-12 Show Promising Clinical Activity in Unresectable Stage III/IV Melanoma," was delivered by John Nemunaitis, M.D., Executive Medical Director of Mary Crowley Medical Research Center.
Help employers find you! Check out all the jobs and post your resume.
comments powered by